TipRanks
Go Ultimate55% OFF

Drugs Made In America Acquisition II Corp. (DMII) Financial Statements

Drugs Made In America Acquisition II Corp. Financial Overview

Drugs Made In America Acquisition II Corp.'s market cap is currently $649.74M. The company's EPS TTM is $0.14; its P/E ratio is 0.26; Drugs Made In America Acquisition II Corp. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24
Income Statement
Total Revenue$ 0.00$ 0.00
Gross Profit$ 0.00$ 0.00
Operating Income$ -1.30M$ -151.72K
EBITDA$ -1.30M$ -151.72K
Net Income$ 4.19M$ -151.72K
Balance Sheet
Cash & Short-Term Investments$ 223.00$ 17.04K
Total Assets$ 504.96M$ 138.06K
Total Debt$ 0.00$ 250.10K
Net Debt$ -223.00$ 233.06K
Total Liabilities$ 17.80M$ 254.78K
Stockholders' Equity$ 487.16M$ -116.72K
Cash Flow
Free Cash Flow$ -1.02M$ -194.30K
Operating Cash Flow$ -1.02M$ -194.30K
Investing Cash Flow$ -500.00M$ 0.00
Financing Cash Flow$ 501.00M$ 211.33K

Currency in USD

Drugs Made In America Acquisition II Corp. Earnings and Revenue History

-2.5M02.5M5M0 %0.4 %0.8 %1.2 %EarningsProfit Margin20242025RevenueEarningsProfit Margin

Drugs Made In America Acquisition II Corp. Debt to Assets

0200M400M600M0 %80 %160 %240 %LiabilitiesDebt to Assets20242025AssetsLiabilitiesDebt to Assets

Drugs Made In America Acquisition II Corp. Cash Flow

-750M-500M-250M0250M500M750M20242025OperatingInvestingFinancing

Drugs Made In America Acquisition II Corp. Forecast EPS vs Actual EPS